The BREEZHALER device provides confidence that the full dose has been taken
The BREEZHALER® device provides certainty that the full dose has been taken
Per cent values represent proportion of patients who supplied a response.
How to use the BREEZHALER device
Watch the following video to learn how to use the BREEZHALER.
Unlock the potential of inhaled asthma care with ENERZAIR® BREEZHALER (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder)
With once-daily ENERZAIR BREEZHALER,1 your patients can live and breathe every moment.
ENERZAIR® BREEZHALER® is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1
*Data derived from studies in COPD patients using available treatments for COPD in the BREEZHALER devices.2,3
†Compared to Accuhaler®, Respimat® and Turbohaler®.2
‡Errors were considered critical if they could have substantially affected dose delivery to the lung.2
§ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) is not licensed for treatment of COPD.1
¶Compared to Ellipta® and HandiHaler®.3
**From a randomised, open-label multicentre, crossover, phase IV study, designed to compare the peak inspiratory flow rate values generated by patients with moderate to very severe airflow obstruction through the BREEZHALER, Ellipta® and HandiHaler® dry powder inhalers.3
††96 pharmacies collected data from 570 adult asthma patients in Australia. Of these, 348 patients were taking preventer/combination medication on a regular basis and were included. All patients who demonstrated incorrect technique at visit 1 were trained to mastery. Of these, data were available for 238 at follow-up visit.4
HandiHaler® and Respimat® are registered trademarks of Boehringer Ingelheim. Ellipta® and Accuhaler® are registered trademarks of GlaxoSmithKline. Turbohaler® is a registered trademark of AstraZeneca.
Indication: ENERZAIR BREEZHALER is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.1
COPD, chronic obstructive pulmonary disease.
- ENERZAIR BREEZHALER Summary of Product Characteristics
- Molimard M et al. Eur Respir J 2017;49:1601794.
- Altman P et al. BMC Pulm Med 2018;18:100.
- Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.